The anti-biofilm and anti-virulence activities of trans-resveratrol and oxyresveratrol against uropathogenic Escherichia coli

References

• Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. 2003. Intracellular bacterial biofilm-like pods in urinary tract infections. Science. 301:105–107. doi: 10.1126/science.1084550
   PubMed Web of Science ®Google Scholar
• Augustine N, Goel AK, Sivakumar KC, Kumar RA, Thomas S. 2014. Resveratrol – a potential inhibitor of biofilm formation in Vibrio cholerae. Phytomedicine. 21:286–289. doi: 10.1016/j.phymed.2013.09.010
   PubMed Web of Science ®Google Scholar
• Bahrani-Mougeot FK, Buckles EL, Lockatell CV, Hebel JR, Johnson DE, Tang CM, Donnenberg MS. 2002. Type 1 fimbriae and extracellular polysaccharides are preeminent uropathogenic Escherichia coli virulence determinants in the murine urinary tract. Mol Microbiol. 45:1079–1093. doi: 10.1046/j.1365-2958.2002.03078.x
   PubMed Web of Science ®Google Scholar
• Beloin C, Roux A, Ghigo JM. 2008. Escherichia coli biofilms. Curr Top Microbiol Immunol. 322:249–289.
   PubMed Web of Science ®Google Scholar
• Bien J, Sokolova O, Bozko P. 2012. Role of uropathogenic Escherichia coli virulence factors in development of urinary tract infection and kidney damage. Int J Nephrol. 2012:681473.
   PubMedGoogle Scholar
• Blango MG, Mulvey MA. 2010. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother. 54:1855–1863. doi: 10.1128/AAC.00014-10
   PubMed Web of Science ®Google Scholar
• Burns SM, Hull SI. 1999. Loss of resistance to ingestion and phagocytic killing by O- and K- mutants of a uropathogenic Escherichia coli O75:K5 strain. Infect Immun. 67:3757–3762.
   PubMed Web of Science ®Google Scholar
• Cegelski L, Pinkner JS, Hammer ND, Cusumano CK, Hung CS, Chorell E, Aberg V, Walker JN, Seed PC, Almqvist F, et al. 2009. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol. 5:913–919. doi: 10.1038/nchembio.242
   PubMed Web of Science ®Google Scholar
• Cho HS, Lee J-H, Cho MH, Lee J. 2015. Red wines and flavonoids diminish Staphylococcus aureus virulence with anti-biofilm and anti-hemolytic activities. Biofouling. 31:1–11. doi: 10.1080/08927014.2014.991319
   PubMed Web of Science ®Google Scholar
• Choi CW, Choi YH, Cha MR, Kim YS, Yon GH, Hong KS, Park WK, Kim YH, Ryu SY. 2011. In vitro BACE-1 inhibitory activity of resveratrol oligomers from the seed extract of Paeonia lactiflora. Planta Med. 77:374–376. doi: 10.1055/s-0030-1250370
   PubMed Web of Science ®Google Scholar
• Coenye T, Brackman G, Rigole P, De Witte E, Honraet K, Rossel B, Nelis HJ. 2012. Eradication of Propionibacterium acnes biofilms by plant extracts and putative identification of icariin, resveratrol and salidroside as active compounds. Phytomedicine. 19:409–412. doi: 10.1016/j.phymed.2011.10.005
   PubMed Web of Science ®Google Scholar
• Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science. 284:1318–1322. doi: 10.1126/science.284.5418.1318
   PubMed Web of Science ®Google Scholar
• Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. 2010. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res. 54:7–16. doi: 10.1002/mnfr.200900437
   PubMed Web of Science ®Google Scholar
• Ferreira S, Domingues F. 2016. The antimicrobial action of resveratrol against Listeria monocytogenes in food-based models and its antibiofilm properties. J Sci Food Agric. 96:4531–4535. doi: 10.1002/jsfa.7669
   PubMed Web of Science ®Google Scholar
• Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. 2015. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 13:269–284. doi: 10.1038/nrmicro3432
   PubMed Web of Science ®Google Scholar
• Floyd KA, Moore JL, Eberly AR, Good JA, Shaffer CL, Zaver H, Almqvist F, Skaar EP, Caprioli RM, Hadjifrangiskou M. 2015. Adhesive fiber stratification in uropathogenic Escherichia coli biofilms unveils oxygen-mediated control of type 1 pili. PLoS Pathog. 11:e1004697. doi: 10.1371/journal.ppat.1004697
   PubMed Web of Science ®Google Scholar
• He Z, Huang Z, Zhou W, Tang Z, Ma R, Liang J. 2016. Anti-biofilm activities from resveratrol against Fusobacterium nucleatum. Front Microbiol. 7:1065.
   PubMed Web of Science ®Google Scholar
• Heydorn A, Nielsen AT, Hentzer M, Sternberg C, Givskov M, Ersboll BK, Molin S. 2000. Quantification of biofilm structures by the novel computer program COMSTAT. Microbiology. 146:2395–2407. doi: 10.1099/00221287-146-10-2395
   PubMed Web of Science ®Google Scholar
• Hwang D, Lim YH. 2015. Resveratrol antibacterial activity against Escherichia coli is mediated by Z-ring formation inhibition via suppression of FtsZ expression. Sci Rep. 5:10029. doi: 10.1038/srep10029
   PubMed Web of Science ®Google Scholar
• Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:218–220. doi: 10.1126/science.275.5297.218
   PubMed Web of Science ®Google Scholar
• Kim Y-G, Lee J-H, Gwon G, Kim S-I, Park JG, Lee J. 2016. Essential oils and eugenols inhibit biofilm formation and the virulence of Escherichia coli O157:H7. Sci Rep. 6:36377. doi: 10.1038/srep36377
   PubMed Web of Science ®Google Scholar
• Klancnik A, Sikic Pogacar M, Trost K, Tusek Znidaric M, Mozetic Vodopivec B, Smole Mozina S. 2017. Anti-Campylobacter activity of resveratrol and an extract from waste Pinot noir grape skins and seeds, and resistance of Camp. jejuni planktonic and biofilm cells, mediated via the CmeABC efflux pump. J Appl Microbiol. 122:65–77. doi: 10.1111/jam.13315
   PubMed Web of Science ®Google Scholar
• Lee J-H, Cho HS, Joo SW, Regmi SC, Kim J-A, Ryu C-M, Ryu SY, Cho MH, Lee J. 2013. Diverse plant extracts and trans-resveratrol inhibit biofilm formation and swarming of Escherichia coli O157:H7. Biofouling. 29:1189–1203. doi: 10.1080/08927014.2013.832223
   PubMed Web of Science ®Google Scholar
• Lee J-H, Cho MH, Lee J. 2011. 3-Indolylacetonitrile decreases Escherichia coli O157:H7 biofilm formation and Pseudomonas aeruginosa virulence. Environ Microbiol. 13:62–73. doi: 10.1111/j.1462-2920.2010.02308.x
   PubMed Web of Science ®Google Scholar
• Lee J-H, Kim Y-G, Lee J. 2017. Carvacrol-rich oregano oil and thymol-rich thyme red oil inhibit biofilm formation and the virulence of uropathogenic Escherichia coli. J Appl Microbiol. 123:1420–1428. doi: 10.1111/jam.13602
   PubMed Web of Science ®Google Scholar
• Lee J-H, Kim Y-G, Ryu SY, Cho MH, Lee J. 2014. Resveratrol oligomers inhibit biofilm formation of Escherichia coli O157:H7 and Pseudomonas aeruginosa. J Nat Prod. 77:168–172. doi: 10.1021/np400756g
   PubMed Web of Science ®Google Scholar
• Lee J-H, Regmi SC, Kim J-A, Cho MH, Yun H, Lee CS, Lee J. 2011. Apple flavonoid phloretin inhibits Escherichia coli O157:H7 biofilm formation and ameliorates colon inflammation in rats. Infect Immun. 79:4819–4827. doi: 10.1128/IAI.05580-11
   PubMed Web of Science ®Google Scholar
• Liu CI, Liu GY, Song Y, Yin F, Hensler ME, Jeng WY, Nizet V, Wang AH, Oldfield E. 2008. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science. 319:1391–1394. doi: 10.1126/science.1153018
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhou J, Qu Y, Yang X, Shi G, Wang X, Hong Y, Drlica K, Zhao X. 2016. Resveratrol antagonizes antimicrobial lethality and stimulates recovery of bacterial mutants. PLoS One. 11:e0153023. doi: 10.1371/journal.pone.0153023
   PubMed Web of Science ®Google Scholar
• Lyons AB. 2000. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 243:147–154. doi: 10.1016/S0022-1759(00)00231-3
   PubMed Web of Science ®Google Scholar
• Ma DSL, Tan LT, Chan KG, Yap WH, Pusparajah P, Chuah LH, Ming LC, Khan TM, Lee LH, Goh BH. 2018. Resveratrol-potential antibacterial agent against foodborne pathogens. Front Pharmacol. 9:102 doi: 10.3389/fphar.2018.00102
   PubMed Web of Science ®Google Scholar
• Minshew BH, Jorgensen J, Counts GW, Falkow S. 1978. Association of hemolysin production, hemagglutination of human erythrocytes, and virulence for chicken embryos of extraintestinal Escherichia coli isolates. Infect Immun. 20:50–54.
   PubMed Web of Science ®Google Scholar
• Oh M, Lee J-H, Bae SY, Seok JH, Kim S, Chung YB, Han KR, Kim KH, Chung MS. 2015. Protective effects of red wine and resveratrol for foodborne virus surrogates. Food Control. 47:502–509. doi: 10.1016/j.foodcont.2014.07.056
   Web of Science ®Google Scholar
• Pratt LA, Kolter R. 1998. Genetic analysis of Escherichia coli biofilm formation: roles of flagella, motility, chemotaxis and type I pili. Mol Microbiol. 30:285–293. doi: 10.1046/j.1365-2958.1998.01061.x
   PubMed Web of Science ®Google Scholar
• Qin N, Tan X, Jiao Y, Liu L, Zhao W, Yang S, Jia A. 2014. RNA-Seq-based transcriptome analysis of methicillin-resistant Staphylococcus aureus biofilm inhibition by ursolic acid and resveratrol. Sci Rep. 4:5467
   PubMed Web of Science ®Google Scholar
• Rivas L, Dykes GA, Fegan N. 2007. A comparative study of biofilm formation by Shiga toxigenic Escherichia coli using epifluorescence microscopy on stainless steel and a microtitre plate method. J Microbiol Methods. 69:44–51. doi: 10.1016/j.mimet.2006.11.014
   PubMed Web of Science ®Google Scholar
• Ryu JH, Beuchat LR. 2005. Biofilm formation by Escherichia coli O157:H7 on stainless steel: effect of exopolysaccharide and curli production on its resistance to chlorine. Appl Environ Microbiol. 71:247–254. doi: 10.1128/AEM.71.1.247-254.2005
   PubMed Web of Science ®Google Scholar
• Snyder JA, Haugen BJ, Lockatell CV, Maroncle N, Hagan EC, Johnson DE, Welch RA, Mobley HL. 2005. Coordinate expression of fimbriae in uropathogenic Escherichia coli. Infect Immun. 73:7588–7596. doi: 10.1128/IAI.73.11.7588-7596.2005
   PubMed Web of Science ®Google Scholar
• Vestergaard M, Ingmer H. 2019. Antibacterial and antifungal properties of resveratrol. Int J Antimicrob Agents. 53:716–723. doi: 10.1016/j.ijantimicag.2019.02.015
   PubMed Web of Science ®Google Scholar
• Welch RA, Burland V, Plunkett G, 3rd, Redford P, Roesch P, Rasko D, Buckles EL, Liou SR, Boutin A, Hackett J, et al. 2002. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proc Natl Acad Sci U S A. 99:17020–17024. doi: 10.1073/pnas.252529799
   PubMed Web of Science ®Google Scholar
• Wiles TJ, Kulesus RR, Mulvey MA. 2008. Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp Mol Pathol. 85:11–19. doi: 10.1016/j.yexmp.2008.03.007
   PubMed Web of Science ®Google Scholar
• Wood TK. 2009. Insights on Escherichia coli biofilm formation and inhibition from whole-transcriptome profiling. Environ Microbiol. 11:1–15. doi: 10.1111/j.1462-2920.2008.01768.x
   PubMed Web of Science ®Google Scholar